Literature DB >> 11455061

A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.

M L Penichet1, J S Dela Cruz, S U Shin, S L Morrison.   

Abstract

Anti-HER2/neu therapy of human HER2/neu expressing malignancies such as breast cancer has shown only partial success in clinical trials. To expand the clinical potential of this approach, we have genetically engineered an anti-HER2/neu human IgG3 fusion protein containing interleukin-2 (IL-2) fused at its carboxyl terminus. Anti-Her2/neu IgG3-(IL-2) retained antibody and cytokine related activity. Treatment of immunocompentent mice with this antibody fusion protein resulted in significant retardation in the subcutaneous (s.c.) growth of CT26-HER2/neu tumors suggesting that anti-HER2/neu IgG3-(IL-2) fusion protein will be useful in the treatment of HER2/neu expressing tumors. We also found that fusing IL-2 to human IgG3 results in a significant enhancement of the murine anti-human antibody (MAHA) response.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11455061

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN： 1093-2607


  7 in total

1.  IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Authors:  Robin Parihar; Julie Dierksheide; Yan Hu; William E Carson
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 2.  Antibody-cytokine fusion proteins: applications in cancer therapy.

Authors:  Elizabeth Ortiz-Sánchez; Gustavo Helguera; Tracy R Daniels; Manuel L Penichet
Journal:  Expert Opin Biol Ther       Date:  2008-05       Impact factor: 4.388

3.  Breast cancer gene therapy using an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences.

Authors:  S Chaurasiya; P Hew; P Crosley; D Sharon; K Potts; K Agopsowicz; M Long; C Shi; M M Hitt
Journal:  Cancer Gene Ther       Date:  2016-05-06       Impact factor: 5.987

Review 4.  Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation.

Authors:  Patrizia Murer; Dario Neri
Journal:  N Biotechnol       Date:  2019-04-13       Impact factor: 5.079

5.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

Review 6.  The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.

Authors:  Meng Michelle Xu; Yang Pu; Yuan Zhang; Yang-Xin Fu
Journal:  Trends Immunol       Date:  2016-01-07       Impact factor: 16.687

Review 7.  Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site.

Authors:  Jonathan D Kiefer; Dario Neri
Journal:  Immunol Rev       Date:  2016-03       Impact factor: 12.988
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.